These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8817465)

  • 1. Prostaglandin H2/thromboxane A2 pathway in platelet aggregation and activity of Dahl salt-sensitive rat--a sulotroban study.
    Somova L
    Methods Find Exp Clin Pharmacol; 1996 Jun; 18(5):309-13. PubMed ID: 8817465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of iloprost on salt-sensitive Dahl rats.
    Somova L
    Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):443-7. PubMed ID: 8577205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
    Hornberger WB; Patscheke H
    Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
    Parise LV; Venton DL; Le Breton GC
    J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
    Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
    Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation.
    Stürzebecher S; Witt W
    Prostaglandins; 1988 Dec; 36(6):751-60. PubMed ID: 2469101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of platelet aggregation in vitro and ex vivo by the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
    Seuter F; Perzborn E; Rosentreter U; Böshagen H; Fiedler VB
    Arzneimittelforschung; 1989 Dec; 39(12):1525-7. PubMed ID: 2624599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the thromboxane receptor antagonist, sulotroban (BM 13.177; SK&F 95587), with streptokinase: demonstration of thrombolytic synergy.
    Kopia GA; Kopaciewicz LJ; Ohlstein EH; Horohonich S; Storer BL; Shebuski RJ
    J Pharmacol Exp Ther; 1989 Sep; 250(3):887-95. PubMed ID: 2528630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
    Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK
    J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
    Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
    Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
    Michel G; Seipp U
    Arzneimittelforschung; 1990 Aug; 40(8):932-8. PubMed ID: 2242087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of cardiovascular disorders in streptozotocin-induced diabetes in rat. II. Correlation between lipid peroxides, thromboxane A2/prostacyclin, and platelet aggregation in different stages of diabetes.
    Somova L; Kamenov V; Doncheva M; Kirilov G; Vassileva M
    Acta Physiol Pharmacol Bulg; 1988; 14(3):57-62. PubMed ID: 3066112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of the protective action of Bay-u-3405, a new specific thromboxane receptor antagonist, in arachidonate-induced sudden death.
    Ma XL; Karasawa A; Lefer AM
    Methods Find Exp Clin Pharmacol; 1991 Mar; 13(2):105-10. PubMed ID: 1906568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
    Mevkh AT; Basevich VV; Varfolomeev SD
    Biokhimiia; 1984 Dec; 49(12):2035-40. PubMed ID: 6441604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice.
    Kashiwagi H; Yuhki K; Kojima F; Kumei S; Takahata O; Sakai Y; Narumiya S; Ushikubi F
    J Pharmacol Exp Ther; 2015 May; 353(2):269-78. PubMed ID: 25740898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist.
    Kotzé HF; Lamprecht S; Badenhorst PN; van Wyk V; Roodt JP; Alexander K
    Thromb Haemost; 1993 Oct; 70(4):672-5. PubMed ID: 8115994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.